Method for diagnosis of severity and prediction of recurrence in eosinophilic inflammatory disease
AssigneeTaiho Pharmaceutical Co., Ltd.
InventorsYoshihiro Urade, Naomi Eguchi, Kosuke Aritake, Sawako Hyo, Hiroshi Takenaka, Ryo Kawata
Life of this patent
Estimating the term…
Abstract
A method is provided for diagnosis of the severity of a condition in an eosinophilic inflammatory disease such as nasal polyp and for prediction of the recurrence of the disease.
Claims10
A method for diagnosis of the severity of eosinophilic inflammatory disease comprising the measurement of the expressed amount of hematopoietic prostaglandin D synthase (H-PGDS) protein or the measurement of the amount of prostaglandin D2 (PGD2) in a sample obtained from an inflammatory site in a subject, wherein the eosinophilic inflammatory disease is chronic sinusitis accompanied by nasal polyp, and wherein a higher expressed amount of hematopoietic prostaglandin D synthase (H-PGDS) or a higher amount of prostaglandin D2 (PGD2) correlates to more severe eosinophilic inflammatory disease.
A method for the prediction of recurrence of eosinophilic inflammatory disease comprising the measurement of the expressed amount of hematopoietic prostaglandin D synthase (H-PGDS) protein or the measurement of the amount of prostaglandin D2 (PGD2) in a sample obtained from an inflammatory site in a subject, wherein the eosinophilic inflammatory disease is chronic sinusitis accompanied by nasal polyp, and wherein a higher expressed amount of hematopoietic prostaglandin D synthase (H-PGDS) or a higher amount of prostaglandin D2 (PGD2) correlates to a higher predicted recurrence rate of eosinophilic inflammatory disease.
Dependencies are inferred from the claim text.